Founded in 2017 by pharmaceutical professionals, Laxxon Medical develops 3D screen-printed drug delivery systems through its proprietary SPID®-Technology. Headquartered in New York City with research and development facilities in Jena, Germany, the company works with pharmaceutical partners on oral dosage forms that can control how active ingredients are released, including projects aimed at making injectable therapies available by mouth. Its platform supports development from small clinical batches through production at up to 1.5 million units per day.